FAK inhibitor 7, identified by its CAS number 2890814-94-3, is a small molecule that serves as an inhibitor of focal adhesion kinase (FAK), a non-receptor tyrosine kinase involved in various cellular processes, including cell adhesion, migration, and survival. This compound is characterized by its ability to disrupt FAK signaling pathways, which can be particularly relevant in cancer research, as FAK is often overexpressed in various tumors and is associated with tumor progression and metastasis. The chemical structure of FAK inhibitor 7 typically includes specific functional groups that enhance its binding affinity to the FAK protein, thereby inhibiting its activity. In vitro and in vivo studies have demonstrated its potential therapeutic applications, particularly in oncology, where targeting FAK may improve treatment outcomes. Additionally, the compound's pharmacokinetic properties, such as solubility and bioavailability, are crucial for its efficacy as a therapeutic agent. Overall, FAK inhibitor 7 represents a promising avenue for research in targeted cancer therapies.

FAK inhibitor 7

2890814-94-3: FAK inhibitor 7, identified by its CAS number 2890814-94-3, is a small molecule that serves as an inhibitor of focal adhesion kinase (FAK), a non-receptor tyrosine kinase involved in various cellular processes, including cell adhesion, migration, and survival. This compound is characterized by its ability to disrupt FAK signaling pathways, which can be particularly relevant in cancer research, as FAK is often overexpressed in various tumors and is associated with tumor progression and metastasis. The chemical structure of FAK inhibitor 7 typically includes specific functional groups that enhance its binding affinity to the FAK protein, thereby inhibiting its activity. In vitro and in vivo studies have demonstrated its potential therapeutic applications, particularly in oncology, where targeting FAK may improve treatment outcomes. Additionally, the compound's pharmacokinetic properties, such as solubility and bioavailability, are crucial for its efficacy as a therapeutic agent. Overall, FAK inhibitor 7 represents a promising avenue for research in targeted cancer therapies.

FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.

CAS 2890814-94-3

FAK inhibitor 7

FAK inhibitor 7

Ref: TM-T200444